RATIONAL TREATMENT OF ACUTERESPIRATORY VIRAL INFECTION USING THE DRUG SEPTOLETE® TOTAL

E. E. Arinina, M. A. Rashid
{"title":"RATIONAL TREATMENT OF ACUTERESPIRATORY VIRAL INFECTION USING THE DRUG SEPTOLETE® TOTAL","authors":"E. E. Arinina, M. A. Rashid","doi":"10.30809/solo.4.2022.1","DOIUrl":null,"url":null,"abstract":"Acute respiratory viral infections (ARVI) are the most common diseases of the human population. Due to the high virulence of pathogens, in some cases they can acquire the character of an epidemic or pandemic. The diversity of the clinical picture, the com- plexity of predicting outcomes makes the problem of rational choice of a drug for the primary treatment of acute respiratory viral infections a key one and poses a difficult task for the pharmacist - the correct, efficient, safe and effective use of a wide range of drugs available on the domestic pharmaceutical market for the treatment of acute respiratory viral infections. During the pharma- cy consultation, the pharmacist has to find out the patient’s complaints, his morbid background, the presence of drug intolerance, as well as a number of other factors, taking into account the pandemic of a new coronavirus infection. Medicines for the treatment of acute respiratory viral infections are presented in most cases as combination drugs that have several mechanisms of action. The possibility of influencing several manifestations of the disease is provided through the use of Septolete® Total, which has not only a favorable efficacy / safety profile, but also distinct economic advantages over analogues, as well as a potential virucidal effect against the causative agent of a new coronavirus COVID-19 infections.","PeriodicalId":266512,"journal":{"name":"Modern organization of drug supply","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2022-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Modern organization of drug supply","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.30809/solo.4.2022.1","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Acute respiratory viral infections (ARVI) are the most common diseases of the human population. Due to the high virulence of pathogens, in some cases they can acquire the character of an epidemic or pandemic. The diversity of the clinical picture, the com- plexity of predicting outcomes makes the problem of rational choice of a drug for the primary treatment of acute respiratory viral infections a key one and poses a difficult task for the pharmacist - the correct, efficient, safe and effective use of a wide range of drugs available on the domestic pharmaceutical market for the treatment of acute respiratory viral infections. During the pharma- cy consultation, the pharmacist has to find out the patient’s complaints, his morbid background, the presence of drug intolerance, as well as a number of other factors, taking into account the pandemic of a new coronavirus infection. Medicines for the treatment of acute respiratory viral infections are presented in most cases as combination drugs that have several mechanisms of action. The possibility of influencing several manifestations of the disease is provided through the use of Septolete® Total, which has not only a favorable efficacy / safety profile, but also distinct economic advantages over analogues, as well as a potential virucidal effect against the causative agent of a new coronavirus COVID-19 infections.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
合理应用septolete®total治疗急性呼吸道病毒感染
急性呼吸道病毒感染(ARVI)是人类最常见的疾病。由于病原体的高毒力,在某些情况下,它们可以获得流行病或大流行的特征。临床情况的多样性,预测结果的复杂性,使得合理选择用于急性呼吸道病毒感染初级治疗的药物成为一个关键问题,也是药剂师面临的一项艰巨任务——正确、高效、安全、有效地使用国内医药市场上广泛的治疗急性呼吸道病毒感染的药物。在药房咨询期间,药剂师必须考虑到新型冠状病毒感染的大流行,找出患者的抱怨,他的病态背景,药物不耐受的存在,以及许多其他因素。在大多数情况下,治疗急性呼吸道病毒感染的药物是具有几种作用机制的联合药物。通过使用Septolete®Total,可以影响疾病的几种表现,该药物不仅具有良好的疗效/安全性,而且与类似物相比具有明显的经济优势,并且对新型冠状病毒COVID-19感染的病原体具有潜在的病毒杀伤作用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
THE STUDY OF THE SOCIAL DEMAND FOR EXTEMPORALLY MANUFACTURED MEDICINES BY THE PHARMACY ORGANIZATION OF THE ROSTOV REGION ANALYSIS OF THE SYSTEM OF PREFERENTIAL DRUG PROVISION FOR OUTPATIENT PATIENTS WITH CORONAVIRUS INFECTION IN THE REPUBLIC OF TATARSTAN THE SYSTEM OF PREFERENTIAL PROVISION OF MEDICINES IN SMOLENSK REGION: MODERN FEATURES AND PROBLEMS DEVELOPMENT OF A SET OF PROPOSALS TO IMPROVE USER INTERACTION WITH THE SITE OF ONLINE PHARMACIES MODERN REQUIREMENTS FOR PHARMACEUTICAL WORKERS: REGULATION AND REAL PHARMACY PRACTICE
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1